Home
Treatments
Research
Advisors
Management
Contact Us
Zoltan Kiss Consulting (ZKC) is a start-up family-owned biotechnological company which is developing, as its primary focus, a human placenta derived protein (ZKCPr1) which has the promise, based on experiments with obese diabetic mice, to treat both general obesity and excess visceral fat more effectively and with no side effects compared to the presently available drugs including the GLP-1 and amylin based ones.
The multiple positive effects of orally administered highly purified ZKCPr1 on fat stores and metabolism from a representative experiment performed with obese diabetic mice are shown in TABLE 1 under the Treatments section.
ZKC also has a research project using two subcutaneously administered human proteins, ZKCPr1 and ZKCPr2, both specifically and greatly (75-90%) reducing excess visceral fat in obese mice, without changing general obesity, as shown in TABLE 2 under the Research section. The significance of the method is that only if both proteins affect the studied physiological disorder at least by 75% without affecting general obesity can one conclude that excess visceral fat is the most likely cause of that effect. This method is suitable to exclude the many possible confounding factors associated with human observation studies. It is needless to emphasize that knowledge of the exact role visceral fat in physiological disorders is an important precondition for planning a treatment which can only be achieved, at least in obese and overweight mice, with ZKCPr1 but no other drug. ZKC is happy to share its research data, for a fee, if requested.